Serum Levels of Interleukin-13 Increase in Subjects with Insulin Resistance but Do Not Correlate with Markers of Low-Grade Systemic Inflammation
Joint Authors
Islas-Andrade, Sergio
Palomera, Leon F.
Manjarrez-Reyna, Aaron N.
Martínez-Reyes, Camilo P.
Meléndez, Guillermo
Gómez-Arauz, Angélica Y.
Torres-Castro, Israel
Olivos-García, Alfonso
Mendoza-Tenorio, Edith
Sánchez-Medina, Gabriela A.
Escobedo, Galileo
Source
Issue
Vol. 2018, Issue 2018 (31 Dec. 2018), pp.1-11, 11 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2018-02-21
Country of Publication
Egypt
No. of Pages
11
Main Subjects
Abstract EN
Experimental evidence in mice suggests a role for interleukin- (IL-) 13 in insulin resistance and low-grade systemic inflammation.
However, IL-13 serum levels have not been assessed in subjects with insulin resistance, and associations of IL-13 with parameters of low-grade systemic inflammation are still unknown.
Our main goal was to examine the systemic levels of IL-13 in patients with insulin resistance, while also studying the relationship of IL-13 with anthropometric, metabolic, and low-grade systemic inflammatory markers.
Ninety-two participants were included in the study and divided into insulin-resistant patients and noninsulin-resistant controls.
Blood levels of IL-13, glucose, insulin, triglycerides, cholesterol, tumor necrosis factor-alpha (TNF-α), IL-10, proinflammatory (Mon-CD11c+CD206−), and anti-inflammatory (Mon-CD11c−CD206+) monocytes, as well as anthropometric parameters, were measured in all volunteers.
Insulin-resistant patients showed 2.5-fold higher serum levels of IL-13 than controls (P<0.0001) and significantly increased values of TNF-α and Mon-CD11c+CD206−, with concomitant reductions in IL-10 and Mon-CD11c−CD206+.
Increased IL-13 was extraordinarily well associated with hyperglycemia (r=0.7362) and hypertriglyceridemia (r=0.7632) but unexpectedly exhibited no significant correlations with TNF-α (r=0.2907), IL-10 (r=−0.3882), Mon-CD11c+CD206− (r=0.2745) or Mon-CD11c−CD206+ (r=−0.3237).
This study demonstrates that IL-13 serum levels are elevated in patients with insulin resistance without showing correlation with parameters of low-grade systemic inflammation.
American Psychological Association (APA)
Martínez-Reyes, Camilo P.& Gómez-Arauz, Angélica Y.& Torres-Castro, Israel& Manjarrez-Reyna, Aaron N.& Palomera, Leon F.& Olivos-García, Alfonso…[et al.]. 2018. Serum Levels of Interleukin-13 Increase in Subjects with Insulin Resistance but Do Not Correlate with Markers of Low-Grade Systemic Inflammation. Journal of Diabetes Research،Vol. 2018, no. 2018, pp.1-11.
https://search.emarefa.net/detail/BIM-1183837
Modern Language Association (MLA)
Martínez-Reyes, Camilo P.…[et al.]. Serum Levels of Interleukin-13 Increase in Subjects with Insulin Resistance but Do Not Correlate with Markers of Low-Grade Systemic Inflammation. Journal of Diabetes Research No. 2018 (2018), pp.1-11.
https://search.emarefa.net/detail/BIM-1183837
American Medical Association (AMA)
Martínez-Reyes, Camilo P.& Gómez-Arauz, Angélica Y.& Torres-Castro, Israel& Manjarrez-Reyna, Aaron N.& Palomera, Leon F.& Olivos-García, Alfonso…[et al.]. Serum Levels of Interleukin-13 Increase in Subjects with Insulin Resistance but Do Not Correlate with Markers of Low-Grade Systemic Inflammation. Journal of Diabetes Research. 2018. Vol. 2018, no. 2018, pp.1-11.
https://search.emarefa.net/detail/BIM-1183837
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1183837